First-in-Human Trial of the A3-Shield System for Stabilizing Abdominal Aortic Aneurysms
A legfontosabb adatok
- Ki végzi
- Angiolutions GmbH
- Hol
- Tashkent (Üzbegisztán)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 12 fő, tervezett
- Kezdés
- 2025. nov. 28.
- Várható befejezés
- 2028. júl.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- A3-Shield Implantation
- A regiszteradat frissítve
- 2026. január 9.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a small abdominal aortic aneurysm (a bulge in the main belly artery) that causes no symptoms. Everyone gets the A3-Shield implant through a catheter.
- Életkor
- 18 years and older
- Nem
- Men and women. Women cannot be pregnant or plan a pregnancy during follow-up.
- A betegség stádiuma
- Spindle-shaped (fusiform) aneurysm below the kidney arteries, with no symptoms. Size 3.0-5.0 cm (1,2–2 in) for men, 3.0 - 4.5 for women. Aortic neck diameter ≥17mm and ≤ 29mm. Enough healthy artery length (≥ 30 mm) to hold the device. Groin arteries large enough for 14F tubes.
A részvétel fő kizáró okai
- Aneurysm that causes symptoms, has burst, or is in the chest or above the kidney arteries, or is infected, inflammatory or from injury
- Any tear in the aortic wall (aortic dissection), or Marfan's Syndrome or Ehlers-Danlos Syndrome
- Heart attack within 180 days, stroke or mini-stroke within 90 days, or severe heart failure (NYHA class III or IV)
- End-stage kidney disease, creatinine > 2.0 mg/dl (177 µmol/L), or being on dialysis
- Bleeding disorders, body mass index ≥ 40 kg/m2, or life expectancy of less than 24 months
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- IC1. Male and female subjects ≥ 18 years at the time of screening. Female subjects must be of non-childbearing potential or otherwise not pregnant and not planning to become pregnant during the study follow-up period
- IC2. Subject has a documented fusiform infrarenal abdominal aortic aneurysm characterized by the following:
- Aneurysm size of 3.0-5.0 cm in maximum diameter for males; 3.0 - 4.5 for females (diameter measured in CTA perpendicular to the line of flow)
- Aortic neck diameter ≥17mm and ≤ 29mm
- Adequate landing zone for a tubular device of ≥ 30 mm length; IC3. Access vessel size and morphology allows endovascular access of 14F (or larger) introducer sheaths and catheters; IC4. Subject (or legal representative) understands the study requirements and the procedures and provided written informed consent; IC5. Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow-up visits
Ki nem vehet részt
- traumatic; EC2. Subject has any type of aortic dissection; EC3. Subject has congenital connective tissue disease, e.g., Marfan's Syndrome or Ehlers-Danlos Syndrome; EC4. Subject has significant (>25% of vessel circumference of aortic neck) aortic mural thrombus at the attachment site that could compromise fixation of the device; EC5. Subject has arterial access that is not acceptable for the device delivery systems as defined in the device Instructions For Use; EC6. Subject has had an acute myocardial infarction within 180 days prior to the index procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation); EC7. Subject has untreated coronary artery disease, which in the opinion of the treating physician, is clinically significant and requires revascularization; EC8. Subject has congestive heart failure (NYHA class III or IV) or high-grade valvular disease; EC9. Subject has had a cerebrovascular accident or transient ischemic attack within the past 90 days prior to study enrollment; EC10. Subject has end-stage renal disease or has a creatinine > 2.0 mg/dl or is on dialysis; EC11. Subject has a history of bleeding diathesis or coagulopathy; EC12. Subject has Hgb <9 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <1,000 cells/mm3; EC13. Subject has had or plans to have an unrelated major surgical or interventional procedure (including trans-aortic interventions) within 30 days prior or post implantation of the device; EC14. Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated or has known hypersensitivity to the device components; EC15. Subject is participating in another investigational drug or device study and has not completed the follow-up required for that study at least 30 days prior to signing the informed consent form in this study; EC16. Subject is morbidly obese (body mass index ≥ 40 kg/m2) or has other documented conditions that inhibit radiographic visualization of the aorta; EC17. Subject has an active infection or chronic systemic illness at the time of the index procedure that may interfere with study objectives; EC18. Subject has current problems with substance abuse.Smoking is NOT an exclusion criterion; EC19. Subject has severe incapacitating dementia; EC20. Subject has a life expectancy of less than 24 months due to comorbid conditions based on the assessment of the investigator at the time of enrollment
- EC1. Subject has an aneurysm that is:
- symptomatic
- ruptured
- thoracic
- suprarenal
- thoraco-abdominal
- isolated ilio-femoral
- mycotic
- inflammatory
- pseudoaneurysmatic
Ez a vizsgálat jelenleg itt érhető el: Üzbegisztán.
- Еzgu Niyат LlcTashkent, ÜzbegisztánContact: Askar Sabirov, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This clinical trial evaluates the safety and feasibility of the A3-Shield implant for stabilising small abdominal aortic aneurysms in adult patients. The study enrolls men and women with small, asymptomatic infrarenal abdominal aortic aneurysms who are eligible for an elective catheter-based procedure.
A teljes eredeti leírásKevesebb
The trial aims to determine whether implantation of the A3-Shield device is technically feasible and whether it is associated with mechanical immobilization of the aneurysm neck. The study also assesses the peri-procedural and safety profile of the device.
Participants will undergo implantation of the A3-Shield device and attend scheduled follow-up visits that include clinical assessments and imaging such as ultrasound and computed tomography. The study does not include randomisation or a separate control group.
A vizsgálat csoportja
- Device implantationA vizsgált kezelés
A3-Shield Implantation
Kezelés: A3-Shield Implantation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- PRemarket INvestigation to Evaluate the Clinical Safety and effectIveness of the Protective "A3- Shield" System for the stabIlIzation of Abdominal Aortic aneurysmS - Pilot Phase
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. január 9.